NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Forecast, Price & News

$2.78

0.00 (0.00%)

(As of 05/31/2023 ET)

Compare

Today's Range: $2.75
▼
$2.82
50-Day Range: $2.45
▼
$3.23
52-Week Range: $2.32
▼
$8.63

Volume: 9,188 shs
Average Volume: 14,058 shs
Market Capitalization: $13.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Aeterna Zentaris MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.41) to ($2.73) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

Medical Sector

945th out of 1,006 stocks

Pharmaceutical Preparations Industry

469th out of 492 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Aeterna Zentaris.

4.0

Short Interest

Percentage of Shares Shorted
1.69% of the float of Aeterna Zentaris has been sold short.
Short Interest Ratio / Days to Cover
Aeterna Zentaris has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Aeterna Zentaris has recently decreased by 14.36%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aeterna Zentaris does not currently pay a dividend.
Dividend Growth
Aeterna Zentaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AEZS.

2.1

News and Social Media Coverage

News Sentiment
Aeterna Zentaris has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Aeterna Zentaris this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.10% of the stock of Aeterna Zentaris is held by insiders.
Percentage Held by Institutions
Only 0.60% of the stock of Aeterna Zentaris is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aeterna Zentaris are expected to grow in the coming year, from ($3.41) to ($2.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aeterna Zentaris is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aeterna Zentaris is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aeterna Zentaris has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aeterna Zentaris (NASDAQ:AEZS) Stock

Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

May 31, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

May 30, 2023 | americanbankingnews.com

Short Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Decreases By 14.4%

June 1, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

May 26, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Friday (AEZS)

May 23, 2023 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com

May 17, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)

May 15, 2023 | finance.yahoo.com

Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

May 15, 2023 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated at StockNews.com

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 14, 2023 | americanbankingnews.com

Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Significant Increase in Short Interest

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)

May 10, 2023 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial Results

May 9, 2023 | finance.yahoo.com

Aeterna Zentaris Reports First Quarter 2023 Financial Results

May 1, 2023 | americanbankingnews.com

Comparing Addex Therapeutics (NASDAQ:ADXN) & Aeterna Zentaris (NASDAQ:AEZS)

April 29, 2023 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com

April 27, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)

April 22, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

April 20, 2023 | americanbankingnews.com

Head-To-Head Review: Homology Medicines (NASDAQ:FIXX) versus Aeterna Zentaris (NASDAQ:AEZS)

April 6, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)

April 6, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)

April 6, 2023 | finance.yahoo.com

Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

April 5, 2023 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

April 5, 2023 | finance.yahoo.com

Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

April 1, 2023 | americanbankingnews.com

Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Large Drop in Short Interest

March 31, 2023 | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for Aeterna Zentaris (NASDAQ:AEZS)

March 31, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Aeterna Zentaris Inc.'s Q1 2024 Earnings (NASDAQ:AEZS)

March 30, 2023 | americanbankingnews.com

Brokers Issue Forecasts for Aeterna Zentaris Inc.'s Q1 2023 Earnings (NASDAQ:AEZS)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Company Calendar

Last Earnings: 3/23/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AEZS
CUSIP: N/A
CIK: 1113423
Web: www.zentaris.com
Phone: (418) 652-8525
Fax: 418-948-9191
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,730,000.00
Net Margins: N/A
Pretax Margin: -389.41%
Return on Equity: -37.47%
Return on Assets: -26.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.88
Quick Ratio: 7.85

Sales & Book Value

Annual Sales: $5.64 million
Price / Sales: 2.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.43 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 4,860,000
Free Float: 4,851,000
Market Cap: $13.49 million
Optionable: Optionable
Beta: 1.38

Social Links

Key Executives

Klaus Wolfgang Paulini
President, Chief Executive Officer & Director

Giuliano La Fratta
Chief Financial Officer & Senior Vice President

Michael Teifel
Chief Scientific Officer & Senior Vice President

Nicola Ammer
Chief Medical Officer & Senior Vice President

Patricia Zahn
Director-Administrative Services & Human Resources

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AEZS Stock - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.
How have AEZS shares performed in 2023?: Aeterna Zentaris' stock was trading at $3.18 at the start of the year. Since then, AEZS shares have decreased by 12.7% and is now trading at $2.7750.
View the best growth stocks for 2023 here.
Are investors shorting Aeterna Zentaris?: Aeterna Zentaris saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 81,700 shares, a decrease of 14.4% from the April 30th total of 95,400 shares. Based on an average daily volume of 15,800 shares, the short-interest ratio is presently 5.2 days. Currently, 1.7% of the company's shares are sold short.
View Aeterna Zentaris' Short Interest.
When is Aeterna Zentaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our AEZS earnings forecast.
How were Aeterna Zentaris' earnings last quarter?: Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.09. The biopharmaceutical company earned $2.49 million during the quarter, compared to analysts' expectations of $1.06 million.
When did Aeterna Zentaris' stock split?: Shares of Aeterna Zentaris reverse split before market open on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).
What is Aeterna Zentaris' stock symbol?: Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
Who are Aeterna Zentaris' major shareholders?: Aeterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Susquehanna International Group LLP (0.00%).
How do I buy shares of Aeterna Zentaris?: Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aeterna Zentaris' stock price today?: One share of AEZS stock can currently be purchased for approximately $2.78.
How much money does Aeterna Zentaris make?: Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $13.49 million and generates $5.64 million in revenue each year. The biopharmaceutical company earns $-22,730,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.
How can I contact Aeterna Zentaris?: Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191.

This page (NASDAQ:AEZS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial